Sign in or create an account.

LinkedIn
Facebook
Google
Required Please enter your valid business email id. Please enter your valid business email id.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By proceeding, you agree to our Terms of Use and Privacy Policy.

For Sellers
Community
Organizers Sponsors Speakers Suppliers
Events Write a Review My events My Profile Write a Review
Join or Sign In

Claim Your Profile Request

Required
Required
Required Invalid Email Address
Required Invalid Number
Required Minimum 50 and maximum 2000 characters allowed.
Privacy Policy
Your request has been received.
Thank you.
Oops! Something went wrong while submitting the form.

Sponsor Contact Request

Required
Required
Required Invalid Email Address
Required Invalid Number
Required Minimum 50 and maximum 2000 characters allowed.
Required
Privacy Policy
Your request has been received.
Thank you.
Oops! Something went wrong while submitting the form.

SPONSOR

Claim Your Profile

BPS Bioscience Inc.

BPS manufactures one of the largest selections of recombinant enzymes, neutralizing antibodies, inhibitor assay kits, lentiviruses and cell lines for drug discovery and continues to expand its drug discovery products.


Contact BPS Bioscience Inc.
Claim Your Profile

Events Sponsored

event-img
(0)
25-27 January 2022
Multi-Functional Cell Therapies Summit
event-img
(0)

25-27 January 2022

Multi-Functional Cell Therapies Summit

About the Multi-Functional Cell Therapies Summit - the Future of Cell Immunotherapy The future of cell therapies is multi-faceted. At the 2nd Multi-Functional Cell Therapies Summit, we are gathering pioneers at the forefront of development to discuss

Event Ended

Virtual

Paid

Healthcare
event-img
(0)
26-28 September 2022
4th RAS-Targeted Drug Development Summit
event-img
(0)

26-28 September 2022

4th RAS-Targeted Drug Development Summit

For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging

Event Ended

USA

Paid

Boston

Healthcare
event-img
(0)
17-20 October 2022
Discovery On Target 2022
event-img
(0)

17-20 October 2022

Discovery On Target 2022

Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules. We

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
04-08 December 2022
Antibody Engineering & Therapeutics
event-img
(0)

04-08 December 2022

Antibody Engineering & Therapeutics

THE #1 ANTIBODY ENGINEERING CONFERENCE FOR ACCELERATING NEXT GENERATION ANTIBODIES TO COMMERCIAL SUCCESS Brand New Session Themes for 2022: How to Develop an Antibody-based Drug from Discovery to IND? Adaptive Immune Receptor Repertoire Data Processi

Event Ended

Hybrid

Paid

 San Diego

Healthcare
event-img
(0)
24-26 January 2023
6th Annual DDR Inhibitors Summit
event-img
(0)

24-26 January 2023

6th Annual DDR Inhibitors Summit

Welcome to the 6th DDR Inhibitors Summit! DNA damage response inhibition has amassed a lot of interest over the last decade as it exposes a massive vulnerability in cancer cells. This has a huge potential to treat many types of tumors such as breast

Event Ended

USA

Paid

Boston

Healthcare
event-img
(0)
24-26 January 2023
6th DDR Inhibitors Summit
event-img
(0)

24-26 January 2023

6th DDR Inhibitors Summit

The 6th DDR Inhibitors Summit 2023 is the premier event for pharmaceutical and biotech researchers to discuss advances, challenges, and new solutions in the field of DDR inhibitors.

Event Ended

USA

Paid

Boston,

Healthcare
event-img
(0)
15-19 May 2023
PEGS Boston 2023
event-img
(0)

15-19 May 2023

PEGS Boston 2023

The world’s largest gathering of protein engineering and biotherapeutics experts is back in Boston! PEGS Boston Summit is the leading biologics event with comprehensive programming covering all aspects of biologic drug development with in-depth prese

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
08-09 August 2023
Emerging Technologies for IO Targeting and Discovery
event-img
(0)

08-09 August 2023

Emerging Technologies for IO Targeting and Discovery

In recent years, Immunotherapy has been at the forefront of oncology research. However, this has not been without issues. Some of which include applications to solid tumors, regulating biodistribution, and serious side effects. During this conference

Event Ended

USA

Paid

Boston

Healthcare
event-img
(0)
25-25 September 2023
Emerging Immune Modulation Strategies
event-img
(0)

25-25 September 2023

Emerging Immune Modulation Strategies

The coronavirus pandemic ignited interest in learning more about immune responses to infections, their downstream effects, and how they can be modulated. It also gave rise to increased awareness of the role of immunity in diseases like cancer, neurod

Event Ended

Hybrid

Paid

Washington, DC

Healthcare
event-img
(0)
25-25 September 2023
Strategies for Targeting Kinases
event-img
(0)

25-25 September 2023

Strategies for Targeting Kinases

There has been growing interest in targeting kinases such as JAK, TYK, IRAK, SIK, CDK, MEK, ERK, RTK, PLK, PI3K, ALK, MAPK, GSK, LRRK, and more for their role in neurodegeneration, inflammation, cancer, autoimmune, and other disorders. However, targe

Event Ended

Hybrid

Paid

Washington, DC

Healthcare
event-img
(0)
26-27 September 2023
Small Molecules Targeting RNA
event-img
(0)

26-27 September 2023

Small Molecules Targeting RNA

The coronavirus pandemic ignited interest in learning more about immune responses to infections, their downstream effects, and how they can be modulated. It also gave rise to increased awareness of the role of immunity in diseases like cancer, neurod

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
26-27 September 2023
AI/ML-Enabled Drug Discovery – Part 1
event-img
(0)

26-27 September 2023

AI/ML-Enabled Drug Discovery – Part 1

Cambridge Healthtech Institute’s two-part conference on Artificial Intelligence (AI)/Machine Learning (ML)-Enabled Drug Discovery will highlight the increasing use of computational tools, AI modeling, algorithms, and data science for identifying nove

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
26-27 September 2023
Proteomics-Driven Drug Discovery
event-img
(0)

26-27 September 2023

Proteomics-Driven Drug Discovery

While finding novel druggable targets and drug modalities for therapeutic intervention remains a top priority for the pharma/biotech industry, identifying and validating "good" targets and leads remains challenging. Cambridge Healthtech Institute’s c

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
26-27 September 2023
GPCR-Based Drug Discovery
event-img
(0)

26-27 September 2023

GPCR-Based Drug Discovery

Cambridge Healthtech Institute's GPCR-Based Drug Discovery conference is now in its 18th year. G protein-coupled receptors (GPCRs), because of their central role in so many cellular processes, are still among the largest class of molecules modulated

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
26-27 September 2023
Small Molecules for Cancer Targets – Part 1
event-img
(0)

26-27 September 2023

Small Molecules for Cancer Targets – Part 1

Small molecule-based therapeutic options against traditionally hard-to-drug intracellular oncology targets (like KRAS) are being discovered at a more rapid pace and a few have even reached the market in the past few years. Not only do small molecules

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
26-27 September 2023
Antibodies Against Membrane Protein Targets – Part 1
event-img
(0)

26-27 September 2023

Antibodies Against Membrane Protein Targets – Part 1

As the industry increasingly shifts its attention to biologics, more attention is being paid to the prospect of developing biotherapeutics against membrane-bound targets. For these large target classes, biologics offer improved selectivity, an altern

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
26-27 September 2023
Protein Degraders and Molecular Glues – Part 1
event-img
(0)

26-27 September 2023

Protein Degraders and Molecular Glues – Part 1

A new generation of molecules are being developed to disrupt protein-protein interactions and to hijack the cell’s natural machinery for targeted protein degradation. Proteolysis-targeting chimeras (PROTACs), molecular glues, and other modalities are

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
26-27 September 2023
Neurodegeneration Targets
event-img
(0)

26-27 September 2023

Neurodegeneration Targets

Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets conference focuses on therapeutic candidates in clinical or earlier stage development that modulate molecules or cellular processes involved in neurodegenerative diseases, especial

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
27-28 September 2023
Protein Degraders and Molecular Glues – Part 2
event-img
(0)

27-28 September 2023

Protein Degraders and Molecular Glues – Part 2

A new generation of molecules are being developed to disrupt protein-protein interactions and to hijack the cell’s natural machinery for targeted protein degradation. Proteolysis-targeting chimeras (PROTACs), molecular glues, and other modalities are

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
27-28 September 2023
Genomics-Driven Drug Discovery
event-img
(0)

27-28 September 2023

Genomics-Driven Drug Discovery

While finding novel druggable targets and drug modalities for therapeutic intervention remains a top priority for the pharma/biotech industry, identifying and validating "good" targets and leads remains challenging. Cambridge Healthtech Institute’s c

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
27-28 September 2023
Lead Generation Strategies
event-img
(0)

27-28 September 2023

Lead Generation Strategies

Cambridge Healthtech Institute’s annual Lead Generation Strategies conference illuminates the latest approaches used by medicinal, biophysical and computational chemists to discover and develop small molecules (and now slightly larger molecules that

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
27-28 September 2023
Antibodies Against Membrane Protein Targets – Part 2
event-img
(0)

27-28 September 2023

Antibodies Against Membrane Protein Targets – Part 2

As the industry increasingly shifts its attention to biologics, more attention is being paid to the prospect of developing biotherapeutics against membrane-bound targets. For these large target classes, biologics offer improved selectivity, an altern

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
27-28 September 2023
Fibrosis and Inflammation
event-img
(0)

27-28 September 2023

Fibrosis and Inflammation

Fibrosis can be viewed as the end-stage of chronic inflammation. Fibrosis and inflammation are related to the immune system gone awry and both underlie many conditions related to aging and therefore are increasing in prevalence in the US. Cambridge H

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
27-28 September 2023
Targeting Transcription Factors
event-img
(0)

27-28 September 2023

Targeting Transcription Factors

Transcription factors are proteins with DNA-binding domains that are involved in gene transcription. They are key cell regulators and alterations in their structure, binding, or activity are often found associated with many abnormalities in cellular

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
27-28 September 2023
AI/ML-Enabled Drug Discovery – Part 2
event-img
(0)

27-28 September 2023

AI/ML-Enabled Drug Discovery – Part 2

Cambridge Healthtech Institute’s two-part conference on Artificial Intelligence (AI)/Machine Learning (ML)-Enabled Drug Discovery will highlight the increasing use of computational tools, AI modeling, algorithms, and data science for identifying nove

Event Ended

Hybrid

Paid

Boston

Healthcare
event-img
(0)
13-16 December 2023
Antibody Engineering & Therapeutics US
event-img
(0)

13-16 December 2023

Antibody Engineering & Therapeutics US

The latest science and research on antibody engineering, design and selection diving into critical topics including Neurodegenerative Diseases, Tumor Microenvironment in Antibody Therapy, Antibody Immune Agonist, Bi-Specifics, ADCs, Protein-Based Deg

Event Ended

Hybrid

Paid

San Diego

Healthcare

COMPANY

WORLD HEAD OFFICE

4275 Executive Sq
La Jolla, CA 92037
United States

GLOBAL OPERATIONS CENTER

301A, 3rd Floor, Delta 1,
Giga Space, Viman Nagar,
Pune, Maharashtra 411014.

  • Contact Us
  • Learning Hub
  • Join Us
  • Contact Us

TOP CATEGORIES

  • Marketing
  • Technology
  • Human Resources
  • Finance
  • Healthcare
  • Learning Hub

community

  • Reviewers
  • Organizers
  • Sponsors
  • Speakers
  • Suppliers
  • Join Us

Policies

  • Privacy Policy
  • Terms of Use
  • Community Guidelines
  • Content Usage Guidelines
  • Legal


Terms of Use     |      Privacy Policy     |       © eventually.com